How much revenue did Biotest generate this year?
Biotest has achieved a revenue of 642.36 M EUR this year.
Biotest Revenue 2024
Biotest Revenue
642.36 M EUR
Ticker
BIO.DE
ISIN
DE0005227201
WKN
522720
In 2024, Biotest's sales reached 642.36 M EUR, a -6.17% difference from the 684.6 M EUR sales recorded in the previous year.
The Biotest Revenue history
| YEAR | REVENUE (undefined EUR) | GROSS MARGIN (%) |
|---|---|---|
| 2026e | 702.32 | 39,91 |
| 2025e | 719.12 | 38,98 |
| 2024e | 642.36 | 43,64 |
| 2023 | 684.6 | 40,94 |
| 2022 | 516.1 | 24,20 |
| 2021 | 515.6 | 15,65 |
| 2020 | 484.2 | 26,87 |
| 2019 | 419.1 | 30,73 |
| 2018 | 400.3 | 33,67 |
| 2017 | 378.1 | 35,44 |
| 2016 | 408 | 41,52 |
| 2015 | 534.6 | 39,08 |
| 2014 | 582 | 38,57 |
| 2013 | 500.8 | 41,45 |
| 2012 | 440 | 41,98 |
| 2011 | 422 | 39,76 |
| 2010 | 412.5 | 39,88 |
| 2009 | 440.2 | 48,23 |
| 2008 | 423 | 51,80 |
| 2007 | 326.4 | 52,88 |
| 2006 | 281.9 | 50,37 |
| 2005 | 237.6 | 46,93 |
| 2004 | 217.9 | 47,59 |
Biotest Revenue, EBIT, Net Income DE0005227201 · 522720
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Biotest, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Biotest from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Biotest’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Biotest. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Biotest’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Biotest’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Biotest’s growth potential.
Biotest Revenue, EBIT and net profit per share
| Date | Biotest Revenue | Biotest EBIT | Biotest Net Income |
|---|---|---|---|
| 2026e | 702.32 M undefined | 315.22 M undefined | 139.74 M undefined |
| 2025e | 719.12 M undefined | 108.07 M undefined | 29.98 M undefined |
| 2024e | 642.36 M undefined | 16.16 M undefined | -2 M undefined |
| 2023 | 684.6 M undefined | 120.3 M undefined | 127 M undefined |
| 2022 | 516.1 M undefined | -16.6 M undefined | -32.49 M undefined |
| 2021 | 515.6 M undefined | -50.2 M undefined | -64.99 M undefined |
| 2020 | 484.2 M undefined | -2.3 M undefined | -32.18 M undefined |
| 2019 | 419.1 M undefined | 1.6 M undefined | -4.81 M undefined |
| 2018 | 400.3 M undefined | 12.7 M undefined | 181.38 M undefined |
| 2017 | 378.1 M undefined | 1.2 M undefined | -3.9 M undefined |
| 2016 | 408 M undefined | 34.5 M undefined | -46.2 M undefined |
| 2015 | 534.6 M undefined | 37.2 M undefined | -82.9 M undefined |
| 2014 | 582 M undefined | 53.6 M undefined | 18.8 M undefined |
| 2013 | 500.8 M undefined | 54 M undefined | 31.6 M undefined |
| 2012 | 440 M undefined | 47.5 M undefined | 33.1 M undefined |
| 2011 | 422 M undefined | 44.4 M undefined | 46 M undefined |
| 2010 | 412.5 M undefined | 42.6 M undefined | 36.6 M undefined |
| 2009 | 440.2 M undefined | 61.8 M undefined | 25.4 M undefined |
| 2008 | 423 M undefined | 55.6 M undefined | 25.4 M undefined |
| 2007 | 326.4 M undefined | 38.5 M undefined | 15.2 M undefined |
| 2006 | 281.9 M undefined | 31.4 M undefined | 16 M undefined |
| 2005 | 237.6 M undefined | 25.3 M undefined | 9.9 M undefined |
| 2004 | 217.9 M undefined | 20.8 M undefined | 4.6 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 217.9 M EUR | 20.8 M EUR | 4.6 M EUR |
| 2005 | 237.6 M EUR | 25.3 M EUR | 9.9 M EUR |
| 2006 | 281.9 M EUR | 31.4 M EUR | 16 M EUR |
| 2007 | 326.4 M EUR | 38.5 M EUR | 15.2 M EUR |
| 2008 | 423 M EUR | 55.6 M EUR | 25.4 M EUR |
| 2009 | 440.2 M EUR | 61.8 M EUR | 25.4 M EUR |
| 2010 | 412.5 M EUR | 42.6 M EUR | 36.6 M EUR |
| 2011 | 422 M EUR | 44.4 M EUR | 46 M EUR |
| 2012 | 440 M EUR | 47.5 M EUR | 33.1 M EUR |
| 2013 | 500.8 M EUR | 54 M EUR | 31.6 M EUR |
| 2014 | 582 M EUR | 53.6 M EUR | 18.8 M EUR |
| 2015 | 534.6 M EUR | 37.2 M EUR | -82.9 M EUR |
| 2016 | 408 M EUR | 34.5 M EUR | -46.2 M EUR |
| 2017 | 378.1 M EUR | 1.2 M EUR | -3.9 M EUR |
| 2018 | 400.3 M EUR | 12.7 M EUR | 181.38 M EUR |
| 2019 | 419.1 M EUR | 1.6 M EUR | -4.81 M EUR |
| 2020 | 484.2 M EUR | -2.3 M EUR | -32.18 M EUR |
| 2021 | 515.6 M EUR | -50.2 M EUR | -64.99 M EUR |
| 2022 | 516.1 M EUR | -16.6 M EUR | -32.49 M EUR |
| 2023 | 684.6 M EUR | 120.3 M EUR | 127 M EUR |
| 2024e | 642.36 M EUR | 16.16 M EUR | -2 M EUR |
| 2025e | 719.12 M EUR | 108.07 M EUR | 29.98 M EUR |
| 2026e | 702.32 M EUR | 315.22 M EUR | 139.74 M EUR |
Biotest stock margins DE0005227201 · 522720
The Biotest margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biotest. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biotest.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Biotest's sales revenue. A higher gross margin percentage indicates that the Biotest retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Biotest's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Biotest's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Biotest's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Biotest. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Biotest's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Biotest Margin History
| Biotest Gross margin | Biotest Profit margin | Biotest EBIT margin | Biotest Profit margin |
|---|---|---|---|
| 2026e | 40.94 % | 44.88 % | 19.9 % |
| 2025e | 40.94 % | 15.03 % | 4.17 % |
| 2024e | 40.94 % | 2.52 % | -0.31 % |
| 2023 | 40.94 % | 17.57 % | 18.55 % |
| 2022 | 24.2 % | -3.22 % | -6.3 % |
| 2021 | 15.65 % | -9.74 % | -12.6 % |
| 2020 | 26.87 % | -0.48 % | -6.65 % |
| 2019 | 30.73 % | 0.38 % | -1.15 % |
| 2018 | 33.67 % | 3.17 % | 45.31 % |
| 2017 | 35.44 % | 0.32 % | -1.03 % |
| 2016 | 41.52 % | 8.46 % | -11.32 % |
| 2015 | 39.08 % | 6.96 % | -15.51 % |
| 2014 | 38.57 % | 9.21 % | 3.23 % |
| 2013 | 41.45 % | 10.78 % | 6.31 % |
| 2012 | 41.98 % | 10.8 % | 7.52 % |
| 2011 | 39.76 % | 10.52 % | 10.9 % |
| 2010 | 39.88 % | 10.33 % | 8.87 % |
| 2009 | 48.23 % | 14.04 % | 5.77 % |
| 2008 | 51.8 % | 13.14 % | 6 % |
| 2007 | 52.88 % | 11.8 % | 4.66 % |
| 2006 | 50.37 % | 11.14 % | 5.68 % |
| 2005 | 46.93 % | 10.65 % | 4.17 % |
| 2004 | 47.59 % | 9.55 % | 2.11 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 47.59 % | 9.55 % | 2.11 % |
| 2005 | 46.93 % | 10.65 % | 4.17 % |
| 2006 | 50.37 % | 11.14 % | 5.68 % |
| 2007 | 52.88 % | 11.8 % | 4.66 % |
| 2008 | 51.8 % | 13.14 % | 6 % |
| 2009 | 48.23 % | 14.04 % | 5.77 % |
| 2010 | 39.88 % | 10.33 % | 8.87 % |
| 2011 | 39.76 % | 10.52 % | 10.9 % |
| 2012 | 41.98 % | 10.8 % | 7.52 % |
| 2013 | 41.45 % | 10.78 % | 6.31 % |
| 2014 | 38.57 % | 9.21 % | 3.23 % |
| 2015 | 39.08 % | 6.96 % | -15.51 % |
| 2016 | 41.52 % | 8.46 % | -11.32 % |
| 2017 | 35.44 % | 0.32 % | -1.03 % |
| 2018 | 33.67 % | 3.17 % | 45.31 % |
| 2019 | 30.73 % | 0.38 % | -1.15 % |
| 2020 | 26.87 % | -0.48 % | -6.65 % |
| 2021 | 15.65 % | -9.74 % | -12.6 % |
| 2022 | 24.2 % | -3.22 % | -6.3 % |
| 2023 | 40.94 % | 17.57 % | 18.55 % |
| 2024e | 40.94 % | 2.52 % | -0.31 % |
| 2025e | 40.94 % | 15.03 % | 4.17 % |
| 2026e | 40.94 % | 44.88 % | 19.9 % |
Biotest Aktienanalyse
What does Biotest do?
Biotest AG is an innovative and successful company that operates in the fields of medicine, pharmacy, and biotechnology. It was founded in 1946 by Dr. Carl Adolf Vorherr in Dreieich near Frankfurt am Main. The company's original focus was on the development, production, and distribution of blood plasma products. In the 1950s, Biotest expanded into the field of transfusion medicine and began to clinically examine and process blood from donors. It became a leading manufacturer of concentrate preparations for the treatment of immune deficiencies and blood coagulation disorders in the 1960s. In the 1970s, the company became a leading manufacturer of monoclonal and polyclonal antibodies and an important research and development facility for biotechnological applications. Biotest today is divided into five research and business areas: Hematology & Immunology, Clinical Immunology, Biotherapeutics, Dermatology, and Research and Development. The company is globally present with locations in Europe, North America, Asia, and South America. It employs over 2,500 people and its products are available in more than 90 countries. It invests in research and development to stay at the forefront of technology and improve global health. Biotest ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Biotest's Sales Figures
The sales figures of Biotest originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Biotest’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Biotest's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Biotest’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Biotest stock
How much was the turnover of the company Biotest compared to the previous year?
The revenue of Biotest has increased by -6.17% decreased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Biotest?
The revenue of Biotest is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Biotest measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Biotest so important for investors?
The revenue of Biotest is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Biotest pay?
Over the past 12 months, Biotest paid a dividend of 0.05 EUR . This corresponds to a dividend yield of about 0.12 %. For the coming 12 months, Biotest is expected to pay a dividend of 0 EUR.
What is the dividend yield of Biotest?
The current dividend yield of Biotest is 0.12 %.
When does Biotest pay dividends?
Biotest pays a quarterly dividend. This is distributed in the months of June, June, June, September.
How secure is the dividend of Biotest?
Biotest paid dividends every year for the past 2 years.
What is the dividend of Biotest?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Biotest located?
Biotest is assigned to the 'Health' sector.
Wann musste ich die Aktien von Biotest kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Biotest from 9/4/2017 amounting to 0.05 EUR, you needed to have the stock in your portfolio before the ex-date on 8/31/2017.
When did Biotest pay the last dividend?
The last dividend was paid out on 9/4/2017.
What was the dividend of Biotest in the year 2023?
In the year 2023, Biotest distributed 0 EUR as dividends.
In which currency does Biotest pay out the dividend?
The dividends of Biotest are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Biotest
Our stock analysis for Biotest Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biotest Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
